<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937960</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300002816</org_study_id>
    <nct_id>NCT03937960</nct_id>
  </id_info>
  <brief_title>Effect of Low Carbohydrate Versus Low Fat Diet in the Treatment of Dyslipidemia in Obese Children With Metabolic Syndrome</brief_title>
  <official_title>Effect of Carbohydrate Restricted Versus Standard Low Fat Diet in the Treatment of Dyslipidemia in Children With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two-arm, parallel design with children between the ages of 10 - 18 with obesity and metabolic
      syndrome randomized (15 per group) to reduced-carbohydrate diet or a reduced-fat diet for 8
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two-arm, parallel design with participants randomized (15 per group) to reduced-carbohydrate
      diet or a reduced-fat diet for 8 weeks. Anthropometric evaluations, lab work for lipid
      levels, insulin and C peptide levels, resting energy expenditure evaluation, DXA scan and
      cardiovascular markers will occur at baseline during the initial clinic visit. Individual
      dietary counseling will be provided at baseline and as well as weekly diet-specific support
      will be provided with a phone call from the PI. Dietary intake will be assessed with weekly
      food records (weeks 1-8). The return visit on week 8 will include a visit identical to the
      initial visit except the resting energy expenditure will not be revaluated, and the
      participants will be asked to answer a questionnaire about the diet they were consuming.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in concentration of serum High density Lipoprotein level in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in concentration of serum High density Lipoprotein in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in concentration of serum Triglyceride level in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in concentration of serum Triglyceride level in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in concentration of serum lipoprotein particle number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in concentration of serum lipoprotein particle number</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in concentration of serum lipoprotein particle concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in concentration of serum lipoprotein particle concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in concentration of serum high density lipoprotein particle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in concentration of serum high density lipoprotein particle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in concentration of serum small low density lipoprotein particle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in concentration of serum small low density lipoprotein particle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in concentration of serum small low density lipoprotein size</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyslipidemia measures</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in concentration of serum small low density lipoprotein size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance indices</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in Serum measure of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance indices</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in Serum measure of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in Dual-energy X-ray absorptiometry (DXA) total body composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in Dual-energy X-ray absorptiometry (DXA) total body composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in Dual-energy X-ray absorptiometry (DXA) body fat content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in Dual-energy X-ray absorptiometry (DXA) body fat content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surrogate markers of vascular endothelial function</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in flow mediated dilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surrogate markers of vascular endothelial function</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in flow mediated dilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surrogate markers of vascular endothelial function</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in Pulse wave velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surrogate markers of vascular endothelial function</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>Change in Pulse wave velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surrogate markers of vascular endothelial function as measured by Augmentation index</measure>
    <time_frame>Baseline</time_frame>
    <description>The Augmentation Index a measure of peripheral arterial stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surrogate markers of vascular endothelial function as measured by Augmentation index</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>The Augmentation Index a measure of peripheral arterial stiffness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Obesity</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Carbohydrate restricted group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose. It will provide a fixed amount of carbohydrate, and a total calorie goal - with proteins and fats to satiety. During the first two weeks of the intervention, carbohydrate (CHO) sources will be primarily derived from leafy greens and non-starchy vegetables and CHO intake will be equally distributed across meals throughout the day. At week three, additional CHO sources will be added back to the diet prescription including nuts, unsweetened yogurt, and low-glycemic fruits such as apples and berries.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard/Low fat diet group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control, low-fat diet will contain 55:25:20 %energy from CHO: protein: fat based on the United States Department of Agriculture (USDA) My Plate Daily Food Plan and our groups previous work. For example, an 1800 kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Carbohydrate restricted group</intervention_name>
    <description>Prescribed low carbohydrate diet with set recipes</description>
    <arm_group_label>Carbohydrate restricted group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard low fat diet</intervention_name>
    <description>Diet with less than 20% total calorie intake from dietary fats</description>
    <arm_group_label>Standard/Low fat diet group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: 3 out of 5 of the following criteria

          -  Metabolic syndrome with dyslipidemia

          -  (HDL &lt;40mg/dL

          -  Triglyceride (TG) TG&gt;150mg/dL)

          -  Glucose intolerance (fasting blood sugar &gt;100mg/dL)

          -  Central adiposity (Waist circumference ≥90th percentile or adult cutoff if lower)

          -  Systolic BP ≥130 mm Hg or diastolic BP ≥85 mm Hg or treatment of previously diagnosed
             hypertension

        Exclusion Criteria:

          -  Patient on medications known to induce dyslipidemia (systemic steroids,
             immunosuppressants)

          -  Pregnancy

          -  Untreated thyroid disease, heart disease, cancer, kidney disease

          -  Children on statin/fibrate treatments or other lipid-lowering medications

          -  Prior surgical procedure for weight control or current weight loss medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhuvana Sunil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BHUVANA SUNIL, MD</last_name>
    <phone>2056386456</phone>
    <email>bsunil@uabmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bhuvana Sunil</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bhuvana Sunil</last_name>
      <phone>205-638-6456</phone>
      <email>bsunil@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>BHUVANA Sunil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BHUVANA SUNIL, MD</last_name>
      <phone>205-638-9107</phone>
      <email>bsunil@uabmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Bhuvana Sunil</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dietary intervention</keyword>
  <keyword>Anthropometric measure</keyword>
  <keyword>Lipid profile</keyword>
  <keyword>Augmentation Index</keyword>
  <keyword>Flow mediated dilation</keyword>
  <keyword>DXA scan</keyword>
  <keyword>Nuclear magnetic resonance lipid profile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

